ArticleThoracic cancer2019
Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments.
Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Clinical Spectrum and Outcomes of SOX1 Antibody-Associated Paraneoplastic Neurological Syndromes: A Chinese Cohort Study.Annals of clinical and translational neurology · 2026Article
- GABAMedComm · 2025Review
- Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis.Annals of clinical and translational neurology · 2025Article
- Long-Term Survivor with Paraneoplastic Cerebellar Ataxia and Small-Cell Lung Cancer.Journal of clinical medicine · 2025Article
- Analysis of risk factors for early detection of cystic lung cancer based on CT genomics and its relationship with pathological invasion.Polish journal of radiology · 2025Article
- Comprehensive Analysis of Paraneoplastic Neurologic Syndrome and PNS-CARE Diagnostic Criteria in Clinical Practice.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer.Cell discovery · 2024Article
- Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.European journal of neurology · 2024Article
- Initial screening for neuronal autoantibodies and their putative impact on survival in patients with small-cell lung cancer.Thoracic cancer · 2024Article
- Paraneoplastic Cerebellar Degeneration Revealing Non-Small Cell Lung Cancer: A Case Report.Cureus · 2024Article
- Clinical characteristics and prognosis analysis of acute symptomatic seizures secondary to autoimmune encephalitis.Frontiers in neurology · 2024Article
- An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes.Neural regeneration research · 2023Article
- AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies.Journal of neuroimmunology · 2023Article
- Posttranslational modifications induce autoantibodies with risk prediction capability in patients with small cell lung cancer.Science translational medicine · 2023Article
- Review
- Anti-Neuronal Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1.Annals of neurology · 2022Article
- [Clinical analysis of 11 cases of lymphoma complicated with paraneoplastic neurological syndrome].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Analysis of the Diagnosis Model of Peripheral Non-Small-Cell Lung Cancer under Computed Tomography Images.Journal of healthcare engineering · 2022Article
- Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?International journal of molecular sciences · 2021Review
- Paraneoplastic sensorimotor neuropathy and ventral cauda equina nerve root enhancement as initial presentation of small cell lung carcinoma: a case study.BMC neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic neurological autoimmunity is often associated with small-cell lung cancer (SCLC), a highly malignant neuroendocrine tumor. Paraneoplastic autoimmunity often correlates with longer survival. We describe the paraneoplastic neurological manifestations of patients with SCLC with and without SCLC-predictive autoantibodies and the correlation between autoimmunity and survival. We reviewed the records of 116 patients (51% male) from the Mayo Clinic with histopathologically confirmed SCLC for whom stored serum was available for neural autoantibody testing. Cancer was limited stage in 41%; the median age at diagnosis was 64 years. Paraneoplastic neurological manifestations were recorded in 61% (decreasing frequency: peripheral neuropathy, dysautonomia, cognitive decline, cerebellar ataxia, neuromuscular junction disorder, seizures, cranial neuropathy, movement disorder, brainstem disorder, or myelopathy). Neural autoantibodies, some with pathogenic potential, were detected in the sera of SCLC patients with and without neurological autoimmunity. The most frequent among patients with neurological manifestations were: anti-neuronal nuclear antibody-type 1, voltage-gated calcium channel (VGCC)-N-type, VGCC-P/Q-type, glutamic acid decarboxylase 65 (GAD65), SOX1, and muscle acetylcholine receptor (AChR); while the most common in patients without neurological manifestations were: GAD65, muscle-AChR, and VGCC-P/Q-type. Neither cancer stage at diagnosis nor survival correlated with neurological manifestations or autoantibody-positivity, except for shorter survival in patients with myelopathy. The only predictor of longer survival was limited-stage disease at diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.